

## Clinical Characteristics of Desflurane in Surgical Patients: Minimum Alveolar Concentration

Ira J. Rampil, M.S., M.D.,\* Stephen H. Lockhart, Ph.D., M.D.,† Maurice S. Zwass, M.D.,\* Natalie Peterson, B.S.,‡ Nobuhiko Yasuda, M.D.,† Edmond I. Eger II, M.D.,§ Richard B. Weiskopf, M.D.,¶ Michael C. Damask, M.D.,\*\*

Desflurane (formerly I-653) is a new inhalational anesthetic with a promising pharmacokinetic profile that includes low solubility in blood and tissue, including fat. Since its lipid solubility is less than that of other volatile agents, it may have lower potency. Low solubility would be expected to increase the rate at which alveolar concentration approaches inspired concentration during induction as well as to increase the rate of elimination of desflurane from blood at emergence. We determined the minimum alveolar concentration (MAC) of desflurane in 44 unpremedicated ASA physical status 1 or 2 patients undergoing elective surgery. We prospectively studied four patient groups distinguished by age and anesthetic regimen: 18-30 versus 31-65 yr and desflurane in 60% N<sub>2</sub>O/40% O<sub>2</sub> versus desflurane in O<sub>2</sub>. Anesthesia was induced with desflurane or desflurane in 60% N<sub>2</sub>O/40% O<sub>2</sub>. MAC was determined by a modification of Dixon's up-and-down method with increments of 0.5% desflurane. The MAC of desflurane in O<sub>2</sub> was  $7.25 \pm 0.0$  (mean  $\pm$  SD) in the 18-30-yr age group, and  $6.0 \pm 0.29$  in the 31-65-yr group; the addition of 60% N<sub>2</sub>O reduced the MAC to  $4.0 \pm 0.29$  and  $2.83 \pm 0.58$ , respectively. The median time from discontinuation of desflurane to an appropriate response to commands was 5.25 min. Desflurane appears to be a mild airway irritant but was well tolerated by all patients. (Key words: Anesthesia, requirements: MAC. Anesthetics, gaseous: nitrous oxide. Anesthetics, volatile: desflurane. Potency, anesthetic: MAC.)

A CLEAR TREND in the development of new anesthetic pharmaceuticals is the formulation of drugs that act more rapidly and are eliminated more quickly. This trend is accentuated by the current interest in ambulatory surgery and its emphasis on short postanesthetic recovery times.

\* Assistant Professor of Anesthesia.

† Fellow in Anesthesia.

‡ Research Assistant.

§ Professor and Vice Chairman for Research, Department of Anesthesia.

¶ Professor of Anesthesia and Physiology; Staff, Cardiovascular Research Institute.

\*\* Associate Director, Clinical Research and Development, Anaquest, Inc.

Received from the Departments of Anesthesia and Physiology and the Cardiovascular Research Institute, University of California, San Francisco, California, and from Anaquest, Inc., Murray Hill, New Jersey. Dr. Yasuda's current affiliation: Department of Anesthesiology, Jikei University, Tokyo, Japan. Accepted for publication September 21, 1990. Supported in part by grants from Anaquest, the Anesthesia Research Foundation, and the National Institutes of Health (grant P01 AG03104A). Presented in part at the Annual Meeting of the American Society of Anesthesiologists, New Orleans, Louisiana, October 1989, and at the Annual Meeting of the International Anesthesia Research Society, 1990.

Address reprint requests to Dr. Rampil: Department of Anesthesia, Room C-450, University of California, San Francisco, California 94143-0648.

Desflurane is a new inhalational anesthetic with a promising pharmacokinetic profile and is now undergoing clinical evaluation.

Desflurane (CF<sub>2</sub>H-O-CFH-CF<sub>3</sub>, formerly I-653) is a substituted (fluorine-for-chlorine) derivative of isoflurane having several physical properties that distinguish it from other potent inhalation agents. Foremost are desflurane's low solubilities in human blood and tissue. Its blood-gas partition coefficient is 0.42,<sup>1,2</sup> which is comparable to that of N<sub>2</sub>O or cyclopropane and one third that of isoflurane. Therefore, changes in the inspired concentration of desflurane produce more rapid changes in alveolar concentration than do changes in other volatile anesthetics. Its oil solubility (18.7) also predicts diminished potency compared to that of halothane or isoflurane, according to the Meyer-Overton hypothesis.

The rapid kinetics of desflurane already have been demonstrated in animals.<sup>3</sup> Desflurane also appears to resist biodegradation<sup>4-6</sup> and does not sensitize the myocardium to epinephrine-induced dysrhythmias.<sup>7</sup> In swine, its hemodynamic<sup>8</sup> and electroencephalographic effects<sup>9</sup> are similar to those observed during equipotent doses of isoflurane. Assessment of the clinical effects of desflurane relative to other agents requires first the determination of its minimum alveolar concentration (MAC). The current study reports the determination of MAC for desflurane in surgical patients and presents observations on its use as a clinical anesthetic.

### Materials and Methods

We enrolled 46 patients after obtaining approval of the protocol from the University of California, San Francisco Committee on Human Research and after obtaining the patients' informed consent. Our patients were 18-65 yr of age and ASA physical status 1 or 2 and were scheduled for an elective operation requiring a skin incision. Exclusion criteria were a history or laboratory evidence of hepatic, renal, cardiac, or central nervous system disease; alcohol or recreational drug abuse; chronic use of a drug that would alter MAC; general anesthesia in the 30 days prior to the scheduled surgery; or current child-bearing potential.

Patients were divided into two groups according to age (18-30 vs. 31-65 yr), and these were further divided into groups to receive desflurane in O<sub>2</sub> or desflurane in N<sub>2</sub>O (60%) and O<sub>2</sub> (table 1).

TABLE 1. Description of Experimental Groups

	18-30/O <sub>2</sub>	31-65/O <sub>2</sub>	18-30/N <sub>2</sub> O	31-65/N <sub>2</sub> O
n	9	11	8	16
Age (yr)	25.6 ± 3.8	48 ± 8.73	24.6 ± 3.5	42.4 ± 9.6
Weight (kg)	79 ± 9	86 ± 19	75 ± 11	76 ± 16
Height (cm)	178 ± 4	171 ± 8	179 ± 9	172 ± 16
MAC (%)	7.25 ± 0.00	6.00 ± 0.29	4.00 ± 0.29	2.83 ± 0.58
Female (%)	45	44	0	13
Duration of surgery (min)	157 ± 76	259 ± 97	214 ± 120	185 ± 130

Values are expressed as means ± SD.

All patients were monitored by continuous electrocardiography and pulse oximetry. Patients received no pre-anesthetic medication. Anesthesia was induced by inhalation of desflurane in O<sub>2</sub> or O<sub>2</sub>/N<sub>2</sub>O *via* face mask. Desflurane was vaporized and delivered by a modified Ohmeda DM-5000 vaporizer. Airway gases were monitored continuously with an infrared absorption spectrometer (Datex PB-254) calibrated to desflurane. During induction, total gas flow rates were approximately 6 l/min, and the inspired concentration of desflurane was increased slowly (approximately 1% per min) until the patient was judged ready for laryngoscopy and tracheal intubation (final range: 10–18%) without the use of muscle relaxants. Eight patients required succinylcholine 1 mg · kg<sup>-1</sup> iv to facilitate intubation. These eight patients were evenly distributed among the four groups, and the relaxant effects had resolved prior to surgical incision. Endotracheal tube cuffs were coated with a thin layer of lidocaine ointment prior to intubation. Signs of airway irritation during induction were assessed by the responsible anesthesiologist with the predefined criteria listed in table 2.

After tracheal intubation, fresh gas flow rates were reduced to 0.5–3 l/min, and the inspired concentration of desflurane was adjusted to maintain a stable end-tidal concentration for at least 10 min at the test concentration selected for the individual patient. End-tidal CO<sub>2</sub> concentrations were maintained in the range 30–35 mmHg with mechanical ventilation. Normothermia was maintained with passive measures.

The test concentration of desflurane for each patient was determined using a modification of Dixon's up-and-down method.<sup>10</sup> In each group the first patient was tested

at a best guess (for MAC) concentration, and subsequent patients were tested at a concentration defined by the previous patient's response to incision. If the previous patient had moved, the test concentration was increased by 0.5% desflurane; in the absence of movement, the desflurane concentration was decreased by 0.5%. A positive response to incision required purposeful movement of an extremity or the head within 1 min after incision. Coughing was not considered a positive response.

Values for MAC were obtained by calculating the mid-point concentration of all independent pairs of patients that involved a crossover (*i.e.*, movement to no movement). Patients were tested until each group had four to five crossovers. MAC was defined as the average of the crossover midpoints in each subgroup. Two patients were excluded from the analysis: one acknowledged a history of chronic, high-dose opioid use only after surgery, and in the other, limited head and neck mobility flexibility precluded timely tracheal intubation.

After assessment of the response to incision, adjuvant drugs, such as opioid or relaxants, were administered when clinically indicated. Intraoperatively, desflurane concentration was adjusted to maintain clinically acceptable anesthesia. Before the anticipated completion of surgery, spontaneous ventilation was initiated, and morphine sulfate or fentanyl was given in doses (approximately 5 mg for morphine sulfate and 50 µg for fentanyl) that did not decrease the respiratory rate to less than 8 breaths per min. Desflurane and N<sub>2</sub>O were continued at concentrations that maintained immobility until surgery was complete. Administration of anesthesia then was discontinued and the gas flow set to 10 l/min O<sub>2</sub>. The time to

TABLE 2. Prevalence of Signs of Airway Irritation

Symptom	Threshold	18-30/O <sub>2</sub>	31-65/O <sub>2</sub>	18-30/N <sub>2</sub> O	31-65/N <sub>2</sub> O
Apnea	>15 s	0	0	0	0
Bronchospasm	Wheezing	0	0	0	0
Cough	Any	56	55	38	50
Laryngospasm	>10 s	0	0	0	12
Secretions	Suction required	45	45	25	38

Values are expressed as percentages.

awakening was measured as the interval between the discontinuation of anesthesia and the patient's acknowledgement of or response to two commands ("open your eyes," and "squeeze my fingers"). We interviewed the patients in the postanesthesia care unit (PACU) and on the 1st and 3rd postoperative days (if possible) to determine the incidence of subjective side effects.

The recorded signs of airway irritation and the patient interview data were analyzed with Kruskal-Wallis analysis of variance (ANOVA) for nonparametric data (with correction for tied ranks). Significance was accepted at  $P < 0.05$ .

### Results

The MAC of desflurane for each group is listed in table 1. As with other anesthetics, the MAC of 18–30-yr-old patients was significantly greater than the MAC of the patients aged 31–65 yr, and MAC decreased by approximately 50% in both age groups with the use of 60% N<sub>2</sub>O.

Induction of anesthesia in the groups given desflurane in O<sub>2</sub> frequently was associated with mild excitement phenomena, such as struggling. Two patients exhibited rapid, rhythmic movement of extremities that appeared to be related to clonus, because the activity increased with rapid limb extension; movement rapidly subsided as the end-tidal concentration of desflurane was increased to achieve the second stage of anesthesia. The incidence and intensity of excitement phenomena were lower in the N<sub>2</sub>O groups.

Signs of minor, self-limited airway irritation were apparent in all groups during induction, but clinically significant airway irritation was limited to two patients in the 31–65-yr, N<sub>2</sub>O group; these two patients required succinylcholine for laryngospasm (table 2). Secretions and coughing were the most common manifestations of irritation; apnea and bronchospasm did not occur. There were no differences in these symptoms between the groups. Most of the episodes of coughing occurred during induction at a time when the end-tidal desflurane concentration was increasing through the range of 6–7%.

Overall, 64% of patients remembered the start of induction and a strong odor (table 3). Some (43%) had found the smell disagreeable. The most common descriptions of the odor were "burning" or "soap" in the nose. Administration of N<sub>2</sub>O significantly reduced the incidence of memory of induction and the incidence of nausea in older patients. Overall, 20 patients complained of nausea: 17 noted this symptom in the PACU, 7 on the 1st postoperative day, and only 1 on the 3rd postoperative day. Twenty-three percent of all younger patients, with comparable incidence in the presence or absence of N<sub>2</sub>O, described some degree of postoperative headache. The mean incidence of emesis was 18%, with no difference between groups. Of the 15 patients who noted impaired concentration, all reported this effect only during the first interview in the PACU.

Emergence from anesthesia was rapid, as indicated in figure 1. For all patients, the median time to awakening was 5.25 min. It is likely that the administration of small doses of opioid slowed emergence both by its sedative effect and by its reduction of alveolar ventilation. This confounding factor could not be avoided since very rapid emergence without analgesia was considered inappropriate patient care.

### Discussion

The Meyer-Overton relationship implies an inverse relationship between a drug's anesthetic potency and its lipophilicity. Desflurane fulfills this relationship in its low tissue solubilities and proportional decrease in potency (fig. 2). Simultaneous administration of 60% (approximately 51–57% of MAC<sup>11,12</sup>) N<sub>2</sub>O reduced MAC by 45% in the 18–30-yr-old patients and by 53% in older patients. This additive effect on the potency of desflurane is comparable to the effect of N<sub>2</sub>O on other volatile agents.<sup>12</sup>

Advancing age is associated with decreasing anesthetic requirements for cyclopropane,<sup>13</sup> halothane,<sup>14</sup> and isoflurane.<sup>12</sup> In our study, for those between the 3rd and the 5th decades, the desflurane anesthetic requirement declined to 83% of 3rd-decade MAC (and to 71% with

TABLE 3. Prevalence of Subjective Symptoms in the 3 Days after Administration of Desflurane

Symptom	18–30/O <sub>2</sub>	31–65/O <sub>2</sub>	18–30/N <sub>2</sub> O	31–65/N <sub>2</sub> O	P
Memory of induction	78	82	88	31	<0.02
Pungent	78	45	25	31	
Headache	22	0	25	0	<0.02
Impaired concentration	33	64	38	13	
Vertigo	22	18	38	6	<0.04
Nausea	44	82	25	31	
Vomiting	11	27	13	19	
Myalgia	0	0	13	6	
Sore throat	44	27	25	13	

Values are expressed as percentages.

Indicated differences reflect inhomogeneity among groups.




FIG. 1. Recovery from desflurane was rapid despite agent clearance via spontaneous ventilation and small doses of opioids. Desflurane was maintained at approximately 1 MAC until the surgical dressing was in place. The intersection of the dashed line with the group data curves represents the point at which 50% of each group was awake and responding to commands.

60%  $N_2O$ ), a decrease comparable to those of other volatile agents (fig. 3). Simultaneously, the potency of  $N_2O$  appeared to increase with increasing age in our patients: its presence increased (in a negative direction) the slope of the change in MAC with age.

Jones *et al.*<sup>15</sup> reported the MAC of desflurane in young (average age 25.6 yr), healthy, male volunteers to be 4.58%, which is 63% of the value we report in surgical patients of similar age. The differences in protocol between these studies probably account for the difference




FIG. 2. The Meyer-Overton hypothesis implies that the product of an anesthetic vapor's oil-gas partition coefficient and its potency (as expressed by MAC) should be constant. The measured data from desflurane falls on the straight line described by other anesthetic gases, demonstrating that desflurane conforms to the Meyer-Overton hypothesis.




FIG. 3. The anesthetic requirement for desflurane (as well as other volatile agents) declines with age. In this graph, each agent's MAC in the third decade of life is normalized to 1. The presence of nitrous oxide appears to accentuate the relative increase in potency of both desflurane and isoflurane with increasing age. Data for agents other than desflurane taken from reference 10 (isoflurane), reference 11 (cyclopropane), and reference 12 (halothane).

in the observed MAC. Jones *et al.* applied 50-Hz tetanic electrical stimulation to the ulnar nerve for a maximum of 30 s (in contrast to our 1-min-duration observations for movement) and took repeated measurements in each subject while monotonically increasing or decreasing the inspired concentration of desflurane until a change in the subject's response to the stimulus changed. However, the determination of MAC is sensitive to the type and intensity of stimulation used,<sup>16</sup> and electrical tetany evidently is less than a supramaximal stimulus.

In summary, desflurane provides satisfactory surgical anesthesia when used alone or in combination with  $N_2O$  or morphine sulfate or both. Rapid elimination of desflurane may result in more rapid full return to alertness and may consequently reduce the stay in the PACU and allow accelerated return to street fitness. This agent is modestly irritating to the airway in unpremedicated patients, but in our study, bronchospasm, laryngospasm, or copious secretions were either absent or mild. Intravenous administration of short-acting agents such as thiopental, propofol, or alfentanil would accelerate induction, and in combination with desflurane might provide an optimal anesthetic regimen for patients undergoing outpatient surgery.

The authors wish to thank Winifred Von Ehrenburg for her excellent editorial assistance in the preparation of this manuscript.

### References

1. Eger EI II: Partition coefficients of I-653 in human blood, saline, and olive oil. *Anesth Analg* 66:971-973, 1987
2. Yasuda N, Targ AG, Eger EI II: Solubility of I-653, sevoflurane, isoflurane, and halothane in human tissues. *Anesth Analg* 69:370-373, 1989
3. Eger EI II, Johnson BH: Rates of awakening from anesthesia with I-653, halothane, isoflurane, and sevoflurane: A test of the effect of anesthetic concentration and duration in rats. *Anesth Analg* 66:977-982, 1987
4. Koblin DD, Eger EI II, Johnson BH, Konopka K, Waskell L: I-653 resists degradation in rats. *Anesth Analg* 67:534-538, 1988
5. Koblin DD, Weiskopf RB, Holmes MA, Konopka K, Rampil IJ, Eger EI II, Waskell L: Metabolism of I-653 and isoflurane in swine. *Anesth Analg* 68:147-149, 1989
6. Sutton TS, Koblin DD, Weiskopf RB, Gruenke LD, Rampil IJ, Waskell L, Eger EI II: Fluoride metabolites following prolonged exposure of volunteers and patients to desflurane. *Anesth Analg*, in press
7. Weiskopf RB, Eger EI II, Holmes MA, Rampil IJ, Johnson B, Brown JG, Yasuda N, Targ AG: Epinephrine-induced premature ventricular contractions and changes in arterial blood pressure and heart rate during I-653, isoflurane, and halothane anesthesia in swine. *ANESTHESIOLOGY* 70:293-298, 1989
8. Weiskopf RB, Holmes MA, Eger EI II, Johnson BH, Rampil IJ, Brown JG: Cardiovascular effects of I-653 in swine. *ANESTHESIOLOGY* 69:303-309, 1988
9. Rampil IJ, Weiskopf RB, Brown JG, Eger EI II, Johnson BH, Holmes MA, Donegan JH: I653 and isoflurane produce similar dose-related changes in the electroencephalogram of pigs. *ANESTHESIOLOGY* 69:298-302, 1988
10. Dixon WJ: Quantal response variable experimentation: The up-and-down method, *Statistics in Endocrinology*. Edited by McArthur JW, Colton T. Cambridge, MIT Press, 1967, pp 251-264
11. Hornbein TF, Eger EI II, Winter PM, Smith G, Wetstone D, Smith KH: The minimum alveolar concentration of nitrous oxide in man. *Anesth Analg* 61:553-556, 1982
12. Stevens WC, Dolan WM, Gibbons RT, White A, Eger EI II, Miller RD, DeJong RH, Elashoff RM: Minimum alveolar concentrations (MAC) of isoflurane with and without nitrous oxide in patients of various ages. *ANESTHESIOLOGY* 42:197-200, 1975
13. Munson ES, Hoffman JC, Eger EI II: Use of cyclopropane to test generality of anesthetic requirement in the elderly. *Anesth Analg* 63:998-1000, 1984
14. Gregory GA, Eger EI II, Munson ES: The relationship between age and halothane requirement in man. *ANESTHESIOLOGY* 30:488-491, 1969
15. Jones RM, Cashman JN, Eger EI II, Damask MC, Johnson BH: Kinetics and potency of I-653 in volunteers. *Anesth Analg* 70:3-7, 1990
16. Eger EI II, Johnson B, Weiskopf RB, Holmes MA, Yasuda N, Targ A, Rampil IJ: Minimum alveolar concentration of I653 and isoflurane in pigs: Definition of a supramaximal stimulus. *Anesth Analg* 67:1174-1176, 1988